



The following applies to XCP / Hereditary Expanded Cancer Panel. Testing is performed to evaluate for the presence of variants in coding regions and extending to +/- 10 base pairs of adjacent intronic sequence on either side of the coding exons of the genes analyzed. In addition, the analysis will cover select noncoding variants. Next-generation sequencing, multiplex ligation-dependent probe amplification (MLPA), and/or a polymerase chain reaction-based quantitative method is performed to test for the presence of copy number variants (CNV) in the genes analyzed. Polymerase chain reaction and gel electrophoresis is performed to test for the presence of the 10 megabase (Mb) inversion of coding exons 1–7 of the *MSH2* gene. Confirmation of select reportable variants may be performed by alternate methodologies based on internal laboratory criteria.

This list is current from December 2024 to the present. This document is intended to highlight additional evaluations for variants of high clinical interest as well as technical limitations. However, this document does not comprehensively reflect all genomic regions covered by this test. For questions regarding transcripts, genes or regions covered, contact the laboratory at 800-533-1710.

Genomic Build: GRCh37 (hg19) unless otherwise specified

Gene	Reference Transcript	Additional Evaluations	Technical Limitations
<i>AIP</i>	NM_003977.4	-	-
<i>ALK</i>	NM_004304.5	-	-
<i>APC</i>	NM_000038.6	Promoter 1A: c.-172 to c.-19 (variants between c.-565 to c.-173 may be detected) Promoter 1B: c.-30632 to c.-30046	-
<i>ATM</i>	NM_000051.3	-	-
<i>AXIN2</i>	NM_004655.4	-	-
<i>BAP1</i>	NM_004656.4	-	-
<i>BARD1</i>	NM_000465.4	-	-
<i>BLM</i>	NM_000057.4	-	-
<i>BMPR1A</i>	NM_004329.2	-	-
<i>BRCA1</i>	NM_007294.4	+/- 20 base pairs of adjacent intronic sequence on either side of the coding exons	-
<i>BRCA2</i>	NM_000059.3	+/- 20 base pairs of adjacent intronic sequence on either side of the coding exons	-
<i>BRIP1</i>	NM_032043.3	-	-
<i>BUB1B</i>	NM_001211.5	-	-
<i>CDC73</i>	NM_024529.4	-	-
<i>CDH1</i>	NM_004360.5	-	-
<i>CDK4</i>	NM_000075.4	-	-
<i>CDKN1B</i>	NM_004064.4	-	-
<i>CDKN2A</i>	NM_000077.4	-	-
<i>CHEK2</i>	NM_007194.4	-	-
<i>CTNNA1</i>	NM_001903.5	-	-
<i>DICER1</i>	NM_177438.2	-	-
<i>DIS3L2</i>	NM_152383.4	-	Sequence variants and CNV in exon 19 may not be detected or reported
<i>EGFR</i>	NM_005228.5	-	-
<i>ELP1</i>	NM_003640.5	-	-
<i>EPCAM</i>	NM_002354.3	-	Analysis for sequence variants will not be performed

Targeted Genes and Methodology Details for Hereditary Cancer Custom Gene Panel (continued)

Gene	Reference Transcript	Additional Evaluations	Technical Limitations
<i>EXT1</i>	NM_000127.2	-	-
<i>EXT2</i>	NM_207122.1	-	-
<i>FANCA</i>	NM_000135.4	-	-
<i>FH</i>	NM_000143.3	-	-
<i>FLCN</i>	NM_144997.7	CNV in noncoding exons 1–3	-
<i>GPC3</i>	NM_004484.4	-	-
<i>GREM1</i>	NM_013372.7	-	Analyzed for CNV duplication of upstream enhancer region only; analyses for sequence variants and additional CNV will not be performed
<i>HOXB13</i>	NM_006361.5	-	-
<i>KIT</i>	NM_000222.2	-	-
<i>LZTR1</i>	NM_006767.4	-	-
<i>MAX</i>	NM_002382.5	-	-
<i>MC1R</i>	NM_002386.3	-	-
<i>MEN1</i>	NM_130799.2	-	-
<i>MET</i>	NM_001127500.3	-	-
<i>MITF</i>	NM_000248.3	-	Analyzed only for the presence of c.952G>A p.E318K (rs149617956); analysis for other sequence variants and CNV will not be performed
<i>MLH1</i>	NM_000249.3	c.-27C>A (rs587779001) c.454-13A>G (rs267607749) c.1990-16_1990-2del (rs267607881)	-
<i>MLH3</i>	NM_001040108.1	-	CNV in exon 5 will not be detected or reported
<i>MSH2</i>	NM_000251.3	10 Mb inversion of exons 1-7	-
<i>MSH3</i>	NM_002439.5	-	-
<i>MSH6</i>	NM_000179.2	-	-
<i>MUTYH</i>	NM_001128425.1	c.504+19_504+31del (rs781222233)	-
<i>NBN</i>	NM_002485.4	-	CNV in exon 16 will not be detected or reported
<i>NF1</i>	NM_000267.3	-	Analysis for sequence variants beyond coding exons +/- 10 base pairs of adjacent intronic sequence will not be performed
<i>NF2</i>	NM_000268.3	-	-
<i>NTHL1</i>	NM_002528.7	-	-
<i>PALB2</i>	NM_024675.4	-	-
<i>PDGFRA</i>	NM_006206.6	-	CNV in exons 17 and 19 will not be detected or reported
<i>PHOX2B</i>	NM_003924.4	-	-
<i>PMS2</i>	NM_000535.7	-	-

Targeted Genes and Methodology Details

for Hereditary Cancer Custom Gene Panel (continued)

Gene	Reference Transcript	Additional Evaluations	Technical Limitations
<i>POLD1</i>	NM_002691.4	-	-
<i>POLE</i>	NM_006231.4	-	-
<i>POT1</i>	NM_015450.3	-	CNV in exon 5 will not be detected or reported
<i>PRKAR1A</i>	NM_002734.4	-	-
<i>PTCH1</i>	NM_000264.5	-	-
<i>PTEN</i>	NM_000314.8	Promoter: c.-1302 to c.-589	-
<i>RAD51B</i>	NM_133509.4	-	-
<i>RAD51C</i>	NM_058216.3	-	-
<i>RAD51D</i>	NM_002878.3	-	-
<i>RB1</i>	NM_000321.2	c.-240 to c.-1	-
<i>RECQL4</i>	NM_004260.3	-	-
<i>REST</i>	NM_005612.5	-	-
<i>RET</i>	NM_020975.6	-	-
<i>RNF43</i>	NM_017763.5	-	-
<i>SDHA</i>	NM_004168.4	-	-
<i>SDHAF2</i>	NM_017841.2	-	-
<i>SDHB</i>	NM_003000.3	-	-
<i>SDHC</i>	NM_003001.3	-	-
<i>SDHD</i>	NM_003002.4	-	-
<i>SMAD4</i>	NM_005359.6	-	-
<i>SMARCA4</i>	NM_001128849.2	-	CNV in exon 27 will not be detected or reported
<i>SMARCB1</i>	NM_003073.5	-	-
<i>SMARCE1</i>	NM_003079.5	-	CNV in exon 2 will not be detected or reported
<i>STK11</i>	NM_000455.5	-	-
<i>SUFU</i>	NM_016169.3	-	-
<i>TMEM127</i>	NM_017849.3	-	-
<i>TP53</i>	NM_000546.5	-	-
<i>TRIP13</i>	NM_004237.4	-	-
<i>TSC1</i>	NM_000368.5	-	-
<i>TSC2</i>	NM_000548.5	-	-
<i>VHL</i>	NM_000551.3	-	-
<i>WRN</i>	NM_000553.6	-	-
<i>WT1</i>	NM_024426.6	-	-

Effective Date	Version	Synopsis of Test Change
June 2023	V2	Updated format (additional columns: Additional Evaluations and Technical Limitations)
December 2024	V3	<i>FLCN</i> : Added CNV detection of noncoding exons 1–3